2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2597

The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action
Abstract Number: 2598

Efficacy of Anti-Tumor Necrosis Factor (TNF) Alpha Therapy, in Patients with Spondylarthritis in the University Center of Rouen in France, Divived to the Berlin Algorithm Modified By the Assessement Spondylarthritis Group: A Ten Years Retrospective Study
Abstract Number: 2599

The Agreement between TNFi Treatment Responses and Fatigue Responses Is Weak to Moderate Suggesting Heterogeneity between Experienced Fatigue and Joint Inflammation: A Danish Population-Based Cohort Study
Abstract Number: 2600

Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial
Abstract Number: 2601

Nonsteroidal Anti-Inflammatory Drugs Attenuate Active Inflammatory Sacroiliac Joint Lesions in Patients with Early Axial Spondyloarthritis
Abstract Number: 2602

Evolution of Patient Characteristics in the Era of Biological Treatment of Psoriatic Arthritis: 18-Year Belgian Experience from Leuven Spondyloarthritis Biologics Cohort (BioSPAR)
Abstract Number: 2603

Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
Abstract Number: 2604

Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials
Abstract Number: 2605

Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Abstract Number: 2606

Long-Term Inhibition of Radiographic Progression with Originator Adalimumab in Patients with Moderate to Severe Psoriatic Arthritis with or without Radiographic Damage at Baseline
Abstract Number: 2607

Early Achievement of ASDAS-Major Improvement in Patients with Ankylosing Spondylitis Treated with TNF-α Blockers Is Associated with a Prominent Longterm Improvement in Metrologic Indices
Abstract Number: 2608

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study
Abstract Number: 2609

Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
Abstract Number: 2610

Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis
Abstract Number: 2611

Multidrug Resistant AxSpA: No Advantage of Switching Class in Patients with Inadequate Response to Two Prior TNFi Agents

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].